Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

Shares jumped 10% pre-market after the FDA approved Rocket Pharmaceuticals' gene therapy for a rare, often fatal pediatric immune disorder — the first regulatory approval for a treatment of this condition. The approval is a transformative clinical and commercial milestone that could materially expand Rocket's addressable market and revenue potential, prompting a likely rerating of the stock.

Analysis

Shares jumped 10% pre-market after the FDA approved Rocket Pharmaceuticals' gene therapy for a rare, often fatal pediatric immune disorder — the first regulatory approval for a treatment of this condition. The approval is a transformative clinical and commercial milestone that could materially expand Rocket's addressable market and revenue potential, prompting a likely rerating of the stock.